专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120027795A1 SIMPLE VACCINES FROM DNA LAUNCHED SUICIDAL FLAVIVIRUSES 审中-公开
标题翻译：从DNA推出的简单的疫苗的简单疫苗
公开(公告)号：US20120027795A1
公开(公告)日：2012-02-02
申请号：US13104909
申请日：2011-05-10
申请人： Matti Sallberg , Lars Frelin , Magnus Johansson
发明人： Matti Sallberg , Lars Frelin , Magnus Johansson
IPC分类号： A61K39/295 , A61P31/18 , A61P31/14
CPC分类号： C07K14/005 , A61K39/12 , A61K39/29 , A61K39/292 , A61K2039/53 , A61K2039/545 , C12N2730/10134 , C12N2770/24134 , C12N2770/24234 , C12N2770/28134 , Y02A50/396
摘要： Immunogenic compositions relating to DNA launched suicidal flaviviruses and methods of administering the same are described herein.
摘要翻译：涉及DNA的自杀性黄病毒的免疫原性组合物及其施用方法在本文中描述。

2. 发明申请

US20140121587A1 INJECTION NEEDLE AND DEVICE 有权
标题翻译：注射针和装置
公开(公告)号：US20140121587A1
公开(公告)日：2014-05-01
申请号：US14125905
申请日：2012-06-13
申请人： Matti Sallberg , Lars Frelin
发明人： Matti Sallberg , Lars Frelin
IPC分类号： A61N1/30
CPC分类号： A61N1/0502 , A61K9/0019 , A61K39/29 , A61K2039/53 , A61K2039/54 , A61M5/3291 , A61M5/3298 , A61M5/46 , A61N1/306 , A61N1/327 , C12M35/02 , C12N7/00 , C12N2730/10134 , C12N2770/24234
摘要： Several needle assemblies and intracellular delivery devices that are used for the delivery of prophylactic and/or therapeutic material (i.e., delivered agents) into a tissue of a subject are disclosed. Preferably, the needle assemblies and/or the intracellular delivery devices comprise needles and/or needle electrodes, which are disposed in an array (e.g., a Y-type array having three outer needles and a center needle), wherein each needle in the array has a closed end and a plurality of apertures along each needle barrel, and the apertures on the needle barrels of the outer needles of the array are positioned to deliver the delivered agent toward the apertures of the center needle and/or an adjacent needle, but not outside of the active zone defined by the area within the needle array and the apertures on the needle barrel of the center needle are positioned to deliver the delivered agent toward the outer needles.
摘要翻译：公开了用于将预防和/或治疗材料（即递送的试剂）递送到受试者的组织中的几个针组件和细胞内递送装置。优选地，针组件和/或细胞内递送装置包括排列成阵列的针和/或针电极（例如，具有三个外针和中心针的Y型阵列），其中阵列中的每个针具有围绕每个针筒的封闭端和多个孔，并且阵列的外针的针筒上的孔定位成将输送的药剂输送到中心针和/或相邻针的孔，但是不在由针阵列内的区域限定的活动区域的外侧，并且中心针的针筒上的孔定位成将输送的药剂朝向外针输送。

3. 发明授权

US09457183B2 Injection needle and device 有权
标题翻译：注射针和装置
公开(公告)号：US09457183B2
公开(公告)日：2016-10-04
申请号：US14125905
申请日：2012-06-13
申请人： Matti Sallberg , Lars Frelin
发明人： Matti Sallberg , Lars Frelin
IPC分类号： A61N1/30 , A61N1/05 , A61N1/32 , C12M1/42 , A61M5/32
CPC分类号： A61N1/0502 , A61K9/0019 , A61K39/29 , A61K2039/53 , A61K2039/54 , A61M5/3291 , A61M5/3298 , A61M5/46 , A61N1/306 , A61N1/327 , C12M35/02 , C12N7/00 , C12N2730/10134 , C12N2770/24234
摘要： Several needle assemblies and intracellular delivery devices that are used for the delivery of prophylactic and/or therapeutic material (i.e., delivered agents) into a tissue of a subject are disclosed. Preferably, the needle assemblies and/or the intracellular delivery devices comprise needles and/or needle electrodes, which are disposed in an array (e.g., a Y-type array having three outer needles and a center needle), wherein each needle in the array has a closed end and a plurality of apertures along each needle barrel, and the apertures on the needle barrels of the outer needles of the array are positioned to deliver the delivered agent toward the apertures of the center needle and/or an adjacent needle, but not outside of the active zone defined by the area within the needle array and the apertures on the needle barrel of the center needle are positioned to deliver the delivered agent toward the outer needles.
摘要翻译：公开了用于将预防和/或治疗材料（即递送的试剂）递送到受试者的组织中的几个针组件和细胞内递送装置。优选地，针组件和/或细胞内递送装置包括排列成阵列的针和/或针电极（例如，具有三个外针和中心针的Y型阵列），其中阵列中的每个针具有围绕每个针筒的封闭端和多个孔，并且阵列的外针的针筒上的孔定位成将输送的药剂输送到中心针和/或相邻针的孔，但是不在由针阵列内的区域限定的活动区域的外侧，并且中心针的针筒上的孔定位成将输送的药剂朝向外针输送。

4. 发明申请

US20120039842A1 COMPOSITIONS AND METHODS THAT ENHANCE AN IMMUNE RESPONSE 失效
标题翻译：提供免疫应答的组合物和方法
公开(公告)号：US20120039842A1
公开(公告)日：2012-02-16
申请号：US13146755
申请日：2010-01-29
申请人： Matti Sallberg , Lars Frelin
发明人： Matti Sallberg , Lars Frelin
IPC分类号： A61K39/29 , A61P37/04 , A61P31/14 , C07H21/04 , A61K38/20
CPC分类号： C07K14/005 , A61K39/12 , A61K39/29 , A61K39/292 , A61K39/39 , A61K2039/5256 , A61K2039/5258 , A61K2039/53 , A61K2039/55516 , A61K2039/55527 , A61K2039/55538 , C07K14/02 , C07K14/1833 , C07K2319/00 , C12N7/00 , C12N2730/10122 , C12N2730/10134 , C12N2770/24222 , C12N2770/24234
摘要： Disclosed herein are isolated nucleic acids, compositions of isolated nucleic acids, and compositions of polypeptides that are useful for the generation, enhancement, or improvement of an immune response to a target antigen. Some embodiments of the compositions include hepatitis B core antigen (HBcAg) protein and a heterologous protein antigen. In some embodiments, an isolated nucleic acid encoding hepatitis B core antigen (HBcAg) protein and a heterologous protein antigen is disclosed. Also disclosed herein are methods of administering the composition or isolated nucleic acid to generate an immune response, where HBcAg acts as adjuvant to improve the immune response to the heterologous protein. In certain embodiments, the HBcAg is as a stork or heron hepatitis antigen.
摘要翻译：本文公开了分离的核酸，分离的核酸的组合物和可用于产生，增强或改善对靶抗原的免疫应答的多肽组合物。组合物的一些实施方案包括乙型肝炎核心抗原（HBcAg）蛋白和异源蛋白质抗原。在一些实施方案中，公开了编码乙型肝炎核心抗原（HBcAg）蛋白和异源蛋白质抗原的分离的核酸。本文还公开了施用组合物或分离的核酸以产生免疫应答的方法，其中HBcAg用作佐剂以改善对异源蛋白的免疫应答。在某些实施方案中，HBcAg是鹳或苍鹭肝炎抗原。

5. 发明授权

US08071561B2 Immunogen platform 有权
标题翻译：免疫原平台
公开(公告)号：US08071561B2
公开(公告)日：2011-12-06
申请号：US12192776
申请日：2008-08-15
申请人： Matti Sallberg , Jonas Soderholm , Lars Frelin
发明人： Matti Sallberg , Jonas Soderholm , Lars Frelin
IPC分类号： A61K48/00 , C12N15/63
CPC分类号： C07K14/005 , A61K39/00 , A61K39/12 , A61K39/29 , A61K39/292 , A61K39/39 , A61K2039/53 , A61K2039/55511 , A61K2039/55566 , A61K2039/57 , A61K2039/572 , A61K2039/575 , C07K2319/00 , C07K2319/50 , C12N7/00 , C12N2730/10122 , C12N2730/10134 , C12N2770/24222 , C12N2770/24234
摘要： Aspects of the present invention relate to chimeric polypeptides including HCV NS3/4A sequences and T-cell epitopes. Embodiments include nucleic acids encoding the chimeric NS3/4A polypeptides, the encoded polypeptides, compositions containing said nucleic acids, compositions containing said chimeric polypeptides, as well as methods of making and using the aforementioned compositions including, but not limited to medicaments and vaccines.
摘要翻译：本发明的方面涉及包括HCV NS3 / 4A序列和T细胞表位的嵌合多肽。实施方案包括编码嵌合NS3 / 4A多肽的核酸，编码的多肽，含有所述核酸的组合物，含有所述嵌合多肽的组合物，以及制备和使用上述组合物的方法，包括但不限于药物和疫苗。

6. 发明申请

US20090214593A1 IMMUNOGEN PLATFORM 审中-公开
标题翻译：免疫平台
公开(公告)号：US20090214593A1
公开(公告)日：2009-08-27
申请号：US12371898
申请日：2009-02-16
申请人： Matti Sallberg , Jonas Soderholm , Lars Frelin
发明人： Matti Sallberg , Jonas Soderholm , Lars Frelin
IPC分类号： A61K39/29 , C07H21/00 , A61K31/7052 , A61P37/04
CPC分类号： A61K39/12 , A61K39/292 , A61K2039/5152 , A61K2039/53 , A61K2039/54 , A61K2039/545 , A61K2039/55516 , A61K2039/57 , C07K14/005 , C07K2319/00 , C12N2730/10122 , C12N2730/10134 , C12N2770/24222 , C12N2770/24234
摘要： Aspects of the present invention relate to chimeric polypeptides including HCV NS3/4A sequences and T-cell epitopes. Embodiments include nucleic acids encoding the chimeric NS3/4A polypeptides, the encoded polypeptides, compositions containing said nucleic acids, compositions containing said chimeric polypeptides, as well as methods of making and using the aforementioned compositions including, but not limited to medicaments and vaccines.
摘要翻译：本发明的方面涉及包括HCV NS3 / 4A序列和T细胞表位的嵌合多肽。实施方案包括编码嵌合NS3 / 4A多肽的核酸，编码的多肽，含有所述核酸的组合物，含有所述嵌合多肽的组合物，以及制备和使用上述组合物的方法，包括但不限于药物和疫苗。

7. 发明申请

US20080295185A1 Transgenic Mouse Models of Hepatitis C Virus (Hcv) and Identification of Hvc Therapeutics 失效
标题翻译：丙型肝炎病毒（Hcv）的转基因小鼠模型和Hvc治疗的鉴定
公开(公告)号：US20080295185A1
公开(公告)日：2008-11-27
申请号：US11660878
申请日：2005-08-26
申请人： Matti Sallberg , Lars Frelin
发明人： Matti Sallberg , Lars Frelin
IPC分类号： G01N33/53 , A01K67/027 , C12N5/10
CPC分类号： A01K67/0275 , A01K2217/052 , A01K2227/105 , A01K2267/0337 , C07K14/005 , C12N15/8509 , C12N2770/24222
摘要： Disclosed herein is the discovery of novel NS3/4A compositions with enhanced expression abilities. Embodiments of the invention include codon optimized NS3/4A compositions and compositions with the Semliki forest virus replicon. Additional embodiments include transgenic organisms containing these NS3/4A compositions, methods or using these transgenic mice to screen and refine drugs, and the drugs refined by these methods. Additional embodiments include protease activity dependent molecules that can indicate the presence or absence of a protease inhibitor.
摘要翻译：本文公开了发现具有增强的表达能力的新型NS3 / 4A组合物。本发明的实施方案包括密码子优化的NS3 / 4A组合物和具有Semliki森林病毒复制子的组合物。另外的实施方案包括含有这些NS3 / 4A组合物的转基因生物，方法或使用这些转基因小鼠筛选和精制药物，以及通过这些方法精制的药物。另外的实施方案包括可以指示蛋白酶抑制剂的存在或不存在的蛋白酶活性依赖性分子。

8. 发明申请

US20160251400A1 HIGH AFFINITY ADAPTOR MOLECULES FOR REDIRECTING ANTIBODY SPECIFITY 审中-公开
标题翻译：用于重定向抗体特异性的高亲和力分子
公开(公告)号：US20160251400A1
公开(公告)日：2016-09-01
申请号：US15013773
申请日：2016-02-02
申请人： Albert Collinson , Peter Wagner , Matti Sallberg , Anders Vahlne , Gregor Schurmann , Robert Kamen
发明人： Albert Collinson , Peter Wagner , Matti Sallberg , Anders Vahlne , Gregor Schurmann , Robert Kamen
IPC分类号： C07K14/00 , C12N15/10
CPC分类号： C07K14/00 , C12N15/1062 , C40B30/04 , C40B40/08 , C40B50/06
摘要： Disclosed are methods for identifying high affinity adaptor molecules that bind to both a circulating antibody and a target molecule and redirect the specificity of the circulating antibody to the target molecule. Exemplary high affinity adaptor molecules are also provided.
摘要翻译：公开了用于鉴定结合循环抗体和靶分子并将循环抗体的特异性重定向到靶分子的高亲和性衔接子分子的方法。还提供了示例性的高亲和性衔接子分子。

9. 发明授权

US08163547B2 Hepatitis C virus codon optimized non-structural NS3/4A fusion gene 有权
公开(公告)号：US08163547B2
公开(公告)日：2012-04-24
申请号：US12894004
申请日：2010-09-29
申请人： Matti Sallberg
发明人： Matti Sallberg
IPC分类号： C12N15/51 , A61K39/29
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , A61K39/12 , A61K39/29 , A61K39/39 , A61K2039/53 , A61K2039/55505 , A61K2039/55511 , A61K2039/57 , A61K2121/00 , A61K2123/00 , C12N7/00 , C12N2730/10134 , C12N2770/24022 , C12N2770/24221 , C12N2770/24222 , C12N2770/24234 , C12N2800/22 , Y02A90/22 , Y02A90/26 , A61K2300/00
摘要： Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.

10. 发明申请

US20110081381A1 HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE 有权
公开(公告)号：US20110081381A1
公开(公告)日：2011-04-07
申请号：US12894014
申请日：2010-09-29
申请人： Matti Sallberg
发明人： Matti Sallberg
IPC分类号： A61K39/29 , A61P31/14
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , A61K39/12 , A61K39/29 , A61K39/39 , A61K2039/53 , A61K2039/55505 , A61K2039/55511 , A61K2039/57 , A61K2121/00 , A61K2123/00 , C12N7/00 , C12N2730/10134 , C12N2770/24022 , C12N2770/24221 , C12N2770/24222 , C12N2770/24234 , C12N2800/22 , Y02A90/22 , Y02A90/26 , A61K2300/00
摘要： Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式